期刊名称：CURRENT PHARMACEUTICAL BIOTECHNOLOGY ISSN： 1389-2010 出版频率： Monthly 出版社： BENTHAM SCIENCE PUBL LTD, EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, SHARJAH, U ARAB EMIRATES, 1200 BR   出版社网址： http://www.bentham.org 期刊网址： http://www.bentham.org/cpb/ 影响因子： 2.837 主题范畴： BIOCHEMISTRY & MOLECULAR BIOLOGY;    PHARMACOLOGY & PHARMACY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. Instructions to Authors Instructions for Authors Manuscripts should be submitted to the Editor-in-Chief without prior invitation at the following address: Dr. Alain P. Rolland Senior Vice President, Product Development Vical, Inc., 9373 Towne Centre Drive Suite 100, San Diego CA 92121-3088 USA Phone: +1-858-646-1208 Fax: +1-858-646-1151 E-mail: arolland@vical.com It is advisable that the authors submit an abstract to the Editor-in-Chief, prior to submitting the full manuscript. The submitted abstract should outline the intended contents and coverage of their article. The manuscript, written in English, should not exceed 60 pages in length and it should be typed in double spacing throughout on A-4 or US Letter (8.5x11 inches) paper. Dot matrix print or any print that is difficult to read is unacceptable. Two copies of the manuscript must accompany the original (along with a computer disk) and should be sent to the Editor at his given address. All pages should be numbered. Abbreviations should be defined the first time that they are used in the manuscript and a list of abbreviations used should also be provided. Manuscript Organization: The manuscript should be divided as: Title page, abstract and the main text. The text may be subdivided further according to the areas to be discussed. This should be followed by the Acknowledgement (if any) and Reference sections. The first page should contain the title, the authors' names (initials and surname only), with an asterisk to mark the name of the principal author. Conflict of Interest: Financial contributions to the work being reported should be clearly acknowledged, as should any potential conflict of interest. Abstract: The abstract should not exceed 250 words and it should condense the essential features of the review article, with the focus on the major advances in the field. Key Words: Authors must supply up to eight key words along with their manuscript. Text: The main text should begin on a separate page and it may be subdivided into separate sections. The review article should mention any previous important reviews in the field and contain a comprehensive discussion starting with the general background of the field. It should then go on to discuss the salient features of recent developments. The authors should avoid presenting material which has already been published in any previous review. The reference numbers should be given in square brackets in the text. Acknowledgements should be kept to a minimum. Tables: Data Tables should be submitted in Microsoft Excel or in Microsoft Word table format. Each table should include a title/caption explaining what the table shows. Detailed legends may then follow. Tables should be given on separate pages with indications on the left hand margin to the text, as to the appropriate placement of the tables. Tables should not contain vertical rules. Columns and rows of data should be made visibly distinct by ensuring the borders of each cell display as black lines. Tables should be numbered consecutively in order of their citation in the body of the text, with Arabic numerals. If a reference is cited in both the table and text, insert a lettered footnote in the table to refer to the numbered reference in the text. Tabular data provided as additional files can be submitted as an Excel spreadsheet. Figures / Illustrations: All authors must strictly follow the guidelines below for preparing illustrations for publication in Current Pharmaceutical Biotechnology. Editorial Requirements: The quality of the illustrations printed in the journal largely depends on the quality of the figures/illustration provided by the author. In preparing artwork or graphics for publication, keep in mind the following points. Submit the original artwork or a photographic print of the original for publication. Do not submit photocopies. (Hardcopy submission requirement). Illustrations should be provided as separate files, not embedded in the text. (Hardcopy submission requirement). Remove all color from graphics except for those illustrations (Greyscale), which are intended to be printed in color. Good quality of hardcopy originals are a requirement. Figures/illustrations cannot be modified or enhanced by the journal production staff. Figures should be referred to as Fig. (1) Fig. (2) etc. in the text with figure numbers in bold within round bracket. Revised manuscripts should contain a complete set of artwork and photographs. Technical Details: Figures should be provided on high quality, white, smooth opaque paper. (Hardcopy requirement). Format & Resolution: The following file formats can be accepted. (Preference in order of appearance): PDF, TIFF, JPEG, GIF. Illustrations must fit a single or double column format on the journal page, according to the following guideline below: HEIGHT WIDTH SINGLE COLUMN 24 cm (max) 8.5 cm (max) DOUBLE COLUMN 24 cm (max) 18 cm (max) Whenever possible, submit graphics that do not have to be reduced to fit the standard figure size. Use the best resolution available (hardcopy submission requirement). For online submission the maximum resolution is 300 dpi. Avoid textures and shadings giving a three-dimensional effect to the illustration. Symbols and lettering in the illustration should be of similar size. Smaller lettering is used. Font: Times New Roman or Helvetica is preferable. Font size: 10pt (maximum). Line drawings should have clear and sharp lines and should be of uniform density. Moreover, lines should be continuous without any breaks. Do not use lines thinner than 1 point. Color Figures / Illustrations: One color plate will be published free of charge in each article. The cost for the first additional published page of color figures is US$ 635; the second additional page will be for US$ 465, and each subsequent page for US$ 315. Color figures should be supplied in CMYK not RGB colors. Required resolution for online submission is 300 dpi. In case of hardcopy submission, please use the maximum resolution available. Photographs: Submit high-contrast prints that are of single- or double-column width so that they will not have to be reduced when printed. Negatives are not acceptable. However, in case of hardcopy submission, color illustrations and plates can be published from 35 mm color slides. Chemical Structures: Chemical structures must be prepared according to the guidelines below. Structures should be prepared using a suitable drawing program e.g. ChemDraw and provided as separate file, submitted both on disk and in printed formats. Numbers in bold should identify all chemical structure. If a name is also used to describe the compound, the associated number in bold should be in parenthesis, e.g. compound (1) Structure Drawing Preferences: [As according to the ACS style sheet] Drawing Settings: Chain angle       120¡ã Bond spacing    18% of width Fixed length       14.4 pt (0.500cm, 0.2in) Bold width          2.0 pt (0.071cm, 0.0278in) Line width           0.6 pt (0.021cm, 0.0084in) Margin width       1.6 pt (0.096cm) Harsh spacing    2.5 pt (0.088cm, 0.0347in) Text settings: Font                    Times New Roman / Helvetica Size                    10pt Under the Preference Choose: Units                    points Tolerances          3 pixels Under Page Setup Use: Paper                  US letter Scale                  100% Structures: The chemical structures must be drawn in ChemDraw (any version) and should be provided as separate file and submitted both on disk and printed formats. The structures should fit into a width of 8 cm (for structures to be inserted within single column widths) or a width of 18 cm (for structures or schemes to be inserted in double column widths). Referance: All references must be numbered in the text in square brackets, e.g. [4], or [7,10-15], in order of citation in the text. Titles of journals are abbreviated according to the Chemical Abstract Service Source Index, example: [1] Robertson, M.P. and Ellington, A.D. (1999) Nat. Biotechnol., 17(1), 62-66. [2] Meyer, M.C.; Straughn, A.B.; Mhatre, R.M.; Shah, V.P.; Williams, R.L. and Lesko L.J. (1998) Pharm. Res., 15(11), 1787-1791. [3] Bebbington, C.R. (1995) in Monoclonal Antibodies - The second generation, (Zola, H., Ed.), Bios Scientific Publishers, Oxford, pp. 165-181. Abstracts, unpublished data and personal communications (which can only be included if the permission has been obtained) should not be given in the reference section but they may be mentioned in the text with details provided as footnotes. All authors of referenced papers must be cited and there must be no use of the short hand version of et al. when citing the authors. Manuscript Submission: Two copies of the manuscript must accompany the original along with the soft copy of the manuscript on a computer floppy disk(s) in MS Word file format (or created in any other well-known word processing software) should be submitted. To achieve rapid publication authors are encouraged to e-mail or fax their submission to the appropriate editorial office (see above) at the same time that they mail the manuscript. For even faster publication, authors are encouraged to submit their entire manuscript via Bentham¡¯s online submission service (see below). Authors must provide their full address, telephone and Fax numbers with E-Mail address with all submissions. For expedient and speedy reviewing of author's manuscripts, authors are strongly advised to include the PDF file of their manuscript on a floppy or zip disk, into the mailing material. At the same time the package is mailed, please also send by e-mail a copy of the PDF file of the manuscript to the editorial office. Online Manuscript Submission: (preferable) To facilitate speedy and cost-effective submission of abstracts and manuscripts, an online submission and tracking service via Internet is being offered. Once the Editor-in-Chief of the journal has accepted your abstract, we would prefer that you submit your full manuscript online via our online submission service available at www.bentham-mps.org For online submission, please provide your complete manuscript in the form of a single zipped folder containing all the material (main text, figures/ illustrations, scanned photographs, tables, chemical structures drawn in ChemDraw) as separate files and a PDF version of the entire manuscript with all the figures/ illustrations / tables / chemical structures etc., embedded in the text exactly in the manner as they should appear in printing. Authors are required to proofread the PDF version of their manuscript before submission. The article will be published exactly as received and the Publishers will not be responsible for any error occurring in the manuscript in this regard. For online submission of manuscripts, these should be submitted via our online manuscript submission service available at www.bentham-mps.org. You may, however, still submit your abstracts and manuscripts through conventional surface mail. Page Charges: No page charges will be levied to authors. Proofs: Authors are sent page proofs. To avoid delays in publication, proofs should be checked immediately for typographical errors and returned within 48 hours. Major changes are not acceptable at the proof stage. Copyright: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication. Bentham Open Access: Accepted articles can be published online for an immediate free open access for all to view. Authors must pay for this service. Reprints: Each first named author will receive a free copy of the journal issue in which their article is published. Reprints may be ordered from the Publisher. First named authors may also order a personal print and online subscription of the journal at 50% off the normal subscription rate by contacting the subscription department at e-mail: subscriptions@bentham.org Reviewing and Promptness of Publication: All papers submitted for publication will be immediately subjected to editorial scrutiny, usually in consultation with members of the Editorial Advisory Board. Every effort will be made to assess the papers quickly. The papers will be typeset and the proofs despatched to the authors normally within 4 weeks of their acceptance. Please provide your telephone and fax numbers with your e-Mail address with all submissions. Editorial Board Editor-in-Chief: Alain Rolland Vical, Inc.,San Diego, CA USA Associate Editors: Seng H. Cheng (Gene Transfer Research, Genzyme Corporation, Framingham, MA, USA) Zeno Foldes-Papp (Medical University of Graz, A-8036 Graz, Austria) Seth P. Monkarsh (Department of Biopharmaceuticals, Hoffmann-La Roche Inc., Nutley, NJ, USA) Cheryl I. Murphy (Aquila Biopharmaceuticals, 175 Crossing Boulevard Suite 200, Framingham, MA, USA) Alice Riggin (Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA) Steven J. Shire (Pharmaceutical R&D Dept., Genentech, Inc., South San Francisco, CA, USA) Editorial Advisory Board: Alessandro Sette (La Jolla Institute for Allergy & Immunology, San Diego, CA USA) Alice Riggin (Lilly Research Laboratories, Indianapolis, USA) Andreas Wiesner (Ciphergen Biosystems, USA) Antonio Grillo-Lopez (Idec Pharmaceuticals, Rancho Santa Fe, CA USA) Arne Holmgren (Karolinska Institutet, Stockholm, Sweden) Aya Jakobovits (UroGenesys) Bruce Meiklejohn (Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA) Cheryl Murphy (RiboNovix, 8 Farrar Road, Lincoln, USA) Colin Pouton (Monash University , Clayton, Victoria 3800, Australia) Cynthia Stevenson (Nektar Therapeutics, San Carlos, CA USA) Dave Allen (Lilly Research Laboratories, USA) Devandra Kalonia (University of CT, USA) Erno Pungor (Berlex Biosciences) Esper Boel (Novo Nordisk, USA) Frank Tagliaferri (Altea Therapeutics, Tucker, USA) Fritz Poulsen (Novo Nordisk, Novo Alle, 2880 Bagsvaerd, Denmark) Gayathri Devi (Duke University Medical Center, Comprehensive Cancer Ctr, Durham, USA) Gillian Francis (PolyMASC Pharmaceuticals) Hartmut Seliger (University Ulm, Ulm, Germany) Jean-Christophe Leroux (University of Montreal, Centre-Ville, Montreal (QC) H3C 3J7, Canada) Jia-yan Wu (Dartmouth Medical School, Dr., Lebanon, NH 03756, USA) John Carpenter (CU Health Services Center, Denver, USA) Kam Leong (Johns Hopkins University, Baltimore, USA) Karl-Otto Greulich (Institute of Biotechnology e.V , Jena, Germany) Kursheed Anwer (Expression Genetics, Huntsville, AL 35801, USA) Lutz Jermutus (Cambridge Antibody Technology , Cambridge, UK) Marcia Moss (BioZyme Inc.1513 Old White Oak, Apex, NC, USA) Mark Manning (Legacy BioDesign, Loveland, CO 80538, USA) Mark Saifer (Mountain View Pharm, Menlo Park, USA) Mary Stickelmeyer (Lilly Research Laboratories, USA) Masataka Kinjo (Hokkaido University, Sapporo, Japan) Peter Goodwin (Los Alamos National Laboratory, Bioscience Division, Los Alamos, USA) Peter Lu (Pacific Northwest National Laboratory, Fundamental Science Division, Richland, USA) Robin Harkness (Sanofi Pasteur Limited, Toronto, ON M2R3T4, Canada) Sean Sullivan (University of Florida, College of Pharmacy, Gainesville, USA) Seng Cheng (Genezyme Corporation, Framingham, USA) Sergey Tetin (Abbott Diagnostics Division, Abbott Park, USA) Seth Monkarsh (Hoffman-La Roche, Nutley, USA) Shuming Nie (Winship Cancer Institute at Emory, Atlanta, USA) Stelios Tzannis (Nektar Therapeutics, San Carlos, CA USA) Theodore Randolph (University of Colorado, University of CO, Boulder, USA) Tom Anchordoquy (CU Health Services Center, School of Pharmacy, Denver, USA) Wolfgang Langhans (Swiss Federal Institute of Technology, Schwerzenbach, Switzerland)